Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: Technical considerations on a clinical series

World Neurosurgery

Volumn 76, Issue 1-2, 2011, Pages 156-159

  Puppa, Alessandro Della ^a   Rossetto, Marta ^a   Ciccarino, Pietro ^a   Denaro, Luca ^a   Rotilio, Antonino ^a   D'Avella, Domenico ^a   Scienza, Renato ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

BCNU wafers; Hydrocephalus; Safety; Ventricular wall defect

Indexed keywords

CARMUSTINE;

ACCURACY; ADULT; AGED; BRAIN EDEMA; BRAIN VENTRICLE CAVITY; CLINICAL ARTICLE; DRUG IMPLANTATION; FOLLOW UP; FRONTAL LOBE; GLIOMA; HUMAN; LIQUORRHEA; MEDICAL PARAMETERS; MENINGITIS; NEUROLOGIC DISEASE; PERIOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; REVIEW; SEIZURE; SURGICAL CAVITY; TEMPORAL LOBE; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CEREBRAL VENTRICLES; COMBINED MODALITY THERAPY; DRUG IMPLANTS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051773224     PISSN: 18788750     EISSN: 18788769     Source Type: Journal    
DOI: 10.1016/j.wneu.2010.10.024     Document Type: Review

References (8)

1. F.J. Attenello, D. Mukherjee, G. Datoo, M.J. McGirt, E. Bohan, J.D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience Ann Surg Oncol 15 2008 2887 2893
2. H. Brem, S. Piantadosi, P.C. Burger, M. Walker, R. Selker, N.A. Vick, K. Black, M. Sisti, S. Brem, G. Mohr, P. Muller, R. Morawetz, S. Clifford Schold Polymer-Brain Tumor Treatment Group Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas Lancet 345 1995 1008 1012
3. J.M. Gallego, J.A. Barcia, and C. Barcia-Mario Fatal outcome related to carmustine implants in glioblastoma multiforme Acta Neurochir (Wien) 149 2007 261 265 [discussion 265] (Pubitemid 46365422)
4. M.J. McGirt, K.D. Than, J.D. Weingart, K.L. Chaichana, F.J. Attenello, A. Olivi, J. Laterra, L.R. Kleinberg, S.A. Grossman, H. Brem, and A. Quiones-HhinojJosa Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 2009 583 588
5. M. Sabel, and A. Giese Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience Cur Med Res Opin 24 2008 3239 3257
6. P. Sampath, and H. Brem Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors Cancer Control 5 1998 130 137 (Pubitemid 28178234)
7. M. Westphal, D.C. Hilt, E. Bortey, P. Delavault, R. Olivares, P.C. Warnke, I.R. Whittle, J. Jaaskelainen, and Z. Ram A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neuro Oncol 5 2003 79 88 (Pubitemid 36422560)
8. Safety information Eisai Inc, 2008 www.gliadel.com Accessed November 29, 2009